Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2025

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol. 2025 doi: 10.1002/art.43188 Epub ahead of print

Aymon R,

Salis Z,

Leeb BF,

Rotar Z,

Nina T,

Data from an international collaboration of registries show no evidence of an increase in CV events during the first 2 years of use with JAKi, compared to TNFi, in the general RA population.

Keywords:

July 2022

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Inanc N,

Leeb BF,

Rotar Z,

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.